Clinical evaluation of anorganic bovine-derived hydroxyapatite matrix/cell-binding peptide (P-15) in the treatment of human infrabony defects

The purpose of the present study was to compare the clinical outcomes of infrabony periodontal defects following treatment with an anorganic bovine-derived hydroxyapatite matrix/cell-binding peptide (ABM/P-15) flow to open flap debridement. Twenty-six patients, each displaying one infrabony defect w...

Full description

Saved in:
Bibliographic Details
Published in:Clinical oral investigations 2008-09, Vol.12 (3), p.241-247
Main Authors: Kasaj, Adrian, Röhrig, Bernd, Reichert, Christoph, Willershausen, Brita
Format: Article
Language:English
Subjects:
Adult
Aged
Alveolar Bone Loss - surgery
Animals
Bone Regeneration
Bone Substitutes
Cattle
Dentistry
Durapatite
Female
Humans
Male
Medicine
Middle Aged
Original Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of the present study was to compare the clinical outcomes of infrabony periodontal defects following treatment with an anorganic bovine-derived hydroxyapatite matrix/cell-binding peptide (ABM/P-15) flow to open flap debridement. Twenty-six patients, each displaying one infrabony defect with probing depth ≥6 mm and vertical radiographic bone loss ≥3 mm participated in the present study. Patients were allocated randomly to be treated with ABM/P-15 flow (test group) or open flap debridement (control group). At baseline and at 12 months after surgery, the following clinical parameters were recorded by a blinded examiner: plaque index, gingival index, probing depth (PD), clinical attachment level (CAL), and gingival recession. Both treatments resulted in significant improvements between baseline and 12 months, in terms of PD reduction and CAL gain ( p  
ISSN:1432-6981
1436-3771
DOI:10.1007/s00784-008-0191-y